APA (7th ed.) Citation

Sekeres, M. A., Santini, V., Díez-Campelo, M., Komrokji, R. S., Fenaux, P., Savona, M. R., . . . Platzbecker, U. (2025). Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study. Leukemia & Lymphoma, 66(3), 529. https://doi.org/10.1080/10428194.2024.2426057

Chicago Style (17th ed.) Citation

Sekeres, Mikkael A., et al. "Sustained Benefits of Imetelstat on Patient-reported Fatigue in Patients with Lower-risk Myelodysplastic Syndromes Ineligible for, or Relapsed/refractory to, Erythropoiesis-stimulating Agents and High Transfusion Burden in the Phase 3 IMerge Study." Leukemia & Lymphoma 66, no. 3 (2025): 529. https://doi.org/10.1080/10428194.2024.2426057.

MLA (9th ed.) Citation

Sekeres, Mikkael A., et al. "Sustained Benefits of Imetelstat on Patient-reported Fatigue in Patients with Lower-risk Myelodysplastic Syndromes Ineligible for, or Relapsed/refractory to, Erythropoiesis-stimulating Agents and High Transfusion Burden in the Phase 3 IMerge Study." Leukemia & Lymphoma, vol. 66, no. 3, 2025, p. 529, https://doi.org/10.1080/10428194.2024.2426057.